drugset / Trial / NCT02954575

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

NCT02954575

Phase 3 Completed 57 enrolled Octapharma
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to obtain additional data on the safety and efficacy of Wilate in PTPs with hemophilia A with at least 150 previous exposure days (EDs) to a FVIII concentrate who undergo prophylactic treatment with Wilate for 6 months and at least 50 EDs, thus supplementing the existing database to obtain approval of Wilate for the indication hemophilia A in the USA.

Timeline

Start
2016-12
Primary completion
2018-03-29
Completion
2018-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Wilate Protein / enzyme biologic

Indications